In the pharmaceutical industry, the design of a facility is neither an architectural exercise nor mere regulatory compliance. It is a strategic decision which conditions the quality of the product, patient safety and the regulatory viability of the project throughout its life cycle.
From a perspective of Quality by Design (QbD), a plant is not designed to “pass an inspection”, but to mitigate product and process specific risks from the conceptual phase. As engineers and validation specialists, we know that many of the problems detected years later by the AEMPS, the FDA or the EMA do not arise in operation, but in a latent design error that was never identified in time.
This article is the first of a series of three technical publications in which we will address, from an engineering and validation perspective, the key principles of pharmaceutical facility design. The objective is to travel the complete path from conceptual design to its defense before a regulatory inspection, connecting regulations, engineering criteria and practical experience.
The philosophy of modern design: risk analysis as a starting point
Before drawing the first line in CAD, the design must be supported by a documented risk analysis, aligned with the ICH Q9 (Quality Risk Management) guide. It is not designed to meet a static standard, but to control real risks associated with the product.
Some examples of key questions that should guide this phase are:
- What is the product sensitivity to light, humidity or temperature?
- What level of toxicity or potency does it present and what containment requirements (OEB 4/5) does it imply for the protection of the operator?
- What is the nature of the product: oral solids, sterile, biotechnological, semisolid?
The answers to these questions determine critical design decisions: area classification, pressure gradients, material selection, HVAC philosophy or level of automation.
The ultimate goal is clear: demonstrate that the Critical Quality Attributes (CQA) of the product will not be compromised by the manufacturing environment.
| Typical error detected in audits | Facilities designed “according to standard” but without clear traceability between CQAs, risk analysis and engineering decisions, making technical defense during a regulatory inspection difficult. |
Design for the life cycle, not just the start-up
A mature pharmaceutical design is not limited to having the plant running on start-up day. You must consider all the GMP life cycle:
- Routine operation under real load,
- Cleaning, maintenance and calibration,
- Product changes or future escalations,
- Requalifications and regulatory updates.
A poorly located valve, an inaccessible probe, or inflexible control logic can turn a minor modification into a complex and expensive requalification project.
Therefore, the design must anticipate:
- Accessibility to critical equipment and instruments
- Operational flexibility
- Ability to demonstrate continuous process control
From regulations to engineering criteria
GMP guidelines, Annex 1, ISO 14644 or ASME BPE standards define what is expected, but not always how to implement it. That's where engineering judgment backed by validation experience comes in. Designing correctly is not applying requirements literally, but interpret them based on risk, the type of product and the operating model of the plant.
In this sense, the design becomes the first and most important validation exercise.
Conclusion: Quality is designed, not inspected
A successful pharmaceutical facility is not one that incorporates the most expensive technology, but rather one that has a coherent, defensible and robust design against risk.
Every decision, from the orientation of a flow to the selection of a material or a control system, must have a technical justification based on patient safety and product integrity.
Accede a los artículos de la serie:
- Pharmaceutical architecture, flows and HVAC systems
- Closing the cycle: From Risk Analysis (QbD) to Objective Evidence of operation
Together, these publications aim to offer an integrated vision of modern pharmaceutical design, based on risk anticipation and real project and inspection experience.
Is your design ready to defend itself in the face of inspection?
Many projects fail not because of lack of investment, but because design decisions not aligned with the real risk of the product.
If you want to evaluate whether your conceptual design, layout or P&ID are correctly aligned with QbD and risk management principles, we can help them through a independent technical review of pharmaceutical design.